Tyra Biosciences to Engage Investors at Major Conferences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a pioneering biotechnology company dedicated to crafting next-generation precision medicines with a keen focus on Fibroblast Growth Factor Receptor (FGFR) biology. The company has great momentum as it takes strides in engaging with investors at a series of crucial investor conferences, highlighting its advanced pipeline and innovative approaches.
Upcoming Investor Conferences
Management at Tyra Biosciences is eager to join the following investor conferences:
Bank of America Global Healthcare Conference
This important event is scheduled to take place over several days, providing a platform for meaningful discussions. The format will include a fireside chat alongside one-on-one investor meetings. Tyra is set to present on:
- Date and Time: Tuesday, the 13th of May at 5:15 PM PT
- Location: Las Vegas
Jefferies Global Healthcare Conference
The next stop will be the Jefferies Global Healthcare Conference, where Tyra will hold one-on-one investor meetings with interested parties, aimed at fostering deeper understanding of its strategic direction and product pipeline. This conference is occurring from June 3rd to June 5th.
UBS Biotech 1x1 Symposium
Additionally, Tyra will participate in the UBS Biotech 1x1 Symposium scheduled for June 24th, again focusing on engaging investors through one-on-one meetings. These tailored interactions are designed to delve into the company’s innovative approaches and the potential of its product candidates.
Webcast Availability
For those who are unable to attend, a live and archived webcast of the fireside chat and other discussions will be made accessible on the Investors section of the Tyra official website.
About Tyra Biosciences
Tyra Biosciences stands at the forefront of precision medicine, utilizing an in-house platform called SNÅP, which fosters rapid and precise drug design. This innovation enables the company to predict genetic alterations that may lead to resistance against existing treatments. With a strong pipeline consisting of three product candidates in clinical development, Tyra positions itself uniquely within the realm of targeted oncology and genetically defined conditions.
The flagship candidate, TYRA-300, emerges as a potential first-in-class FGFR3 inhibitor, meticulously engineered to bypass the side effects commonly associated with inhibiting FGFR1, FGFR2, and FGFR4. This candidate aims to address unmet medical needs in various patient populations through several Phase 2 studies focused on conditions like non-muscle invasive bladder cancer and pediatric achondroplasia.
Complementing this, the company is developing TYRA-200, an oral investigational FGFR1/2/3 inhibitor currently in the SURF201 study, targeting metastatic intrahepatic cholangiocarcinoma. Furthermore, TYRA-430, another oral investigational option, is being tested for its application in FGFR4-driven cancers.
Engagement and More Information
For continuous updates on its scientific advancements and product pipeline, interested individuals can visit the official Tyra Biosciences website to discover more. Additionally, there are opportunities to engage with the company on LinkedIn.
Frequently Asked Questions
What is Tyra Biosciences known for?
Tyra Biosciences specializes in the development of precision medicines targeting FGFR biology.
What will Tyra present at the Bank of America conference?
Tyra will hold a fireside chat and one-on-one meetings to discuss its innovations and pipeline.
Where can I find more information about Tyra's pipeline?
Additional details about Tyra's science and pipeline can be found on their official website.
How does Tyra's platform support drug development?
Tyra utilizes SNÅP, which facilitates rapid drug design by predicting genetic alterations likely to cause resistance to existing therapies.
When is Tyra participating in the UBS Biotech Symposium?
Tyra is set to participate on June 24 at the UBS Biotech Symposium, focusing on investor interactions.
